Lung Cancer in Europe & Central Asia

Lung cancer is the leading cause of cancer death worldwide, killing approximately 1.8 million people annually — more than breast, colon, and prostate cancers combined. Tobacco smoking causes approximately 80-85% of lung cancer cases, with risk proportional to duration and intensity of exposure. Other risk factors include secondhand smoke, radon gas, asbestos, outdoor air pollution, and occupational carcinogens. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of cases, with small-cell lung cancer (SCLC) comprising the remainder. Lung cancer is typically diagnosed at an advanced stage, contributing to a five-year survival rate of only 10-20% globally. Countries with mature tobacco epidemics — including China, the United States, and much of Europe — have the highest incidence, while rates are rising rapidly in countries undergoing tobacco transition. The lung cancer burden is shifting toward low- and middle-income countries as smoking prevalence increases in Asia and Africa. Europe and Central Asia benefit from relatively strong health systems and high physician density, but face ageing populations, rising non-communicable disease burdens, and persistent East-West health outcome gradients. In Europe & Central Asia, lung cancer mortality is near global averages, though the region exhibits a marked gradient between Western European countries with low rates and Central Asian nations facing higher burdens.

Tobacco cessation is the single most effective lung cancer prevention strategy. Even after decades of smoking, quitting substantially reduces risk. Population-level tobacco control — taxation, advertising bans, smoke-free legislation, and graphic health warnings — remains the highest-impact public health intervention. Low-dose CT screening reduces lung cancer mortality by 20-24% in high-risk current and former smokers. Radon mitigation in homes and occupational exposure limits for asbestos and industrial carcinogens complement tobacco control. Immunotherapy and targeted therapies have improved advanced-stage survival.

The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.

The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for lung cancer in Europe & Central Asia, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.

Cancer mortality data combine information from population-based cancer registries, vital registration systems, and statistical modeling where direct data are sparse. Incidence-to-mortality ratios and survival estimates help distinguish regions where high death rates stem from high incidence versus those where limited access to early detection and treatment drives poor outcomes. For lung cancer across Europe & Central Asia, comparing mortality rates alongside screening coverage and treatment availability provides crucial context for understanding regional disparities.

Global Lung Cancer All Europe & Central Asia Data All Cancer Deaths Global Explorer Lung Cancer in East Asia & Pacific Lung Cancer in Latin America & Caribbean Lung Cancer in Middle East, North Africa, Afghanistan & Pakistan